中國光大控股(00165.HK)中期歸屬股東淨虧損12.82億港元
格隆匯8月29日丨中國光大控股(00165.HK)發佈公吿,截至2024年6月30日止六個月,集團收入總額為虧損港幣1.14億元,去年同期為港幣收入15.40億元,較去年同期減少港幣16.54億元。投資虧損方面,受股權投資市場下行壓力,未實現投資虧損進一步擴大,投資收益淨額由去年同期投資收益轉為虧損,較去年同期下跌港幣11.22億元;客户合約收入方面,較去年同期減少港幣1.08億元,主要原因為表現費及諮詢費收入未及預期。
報吿期內,歸屬於公司股東的淨虧損為港幣12.82億元,去年為盈利港幣3.13億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.